Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis
- Sponsor
- Janssen-Cilag Ltd.
- Study ID
- NCT05125679
- Phase
- PHASE4
- Status
- Terminated
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Guselkumab — DRUGGuselkumab will be administered by subcutaneous injection.
Study Details
The purpose of this study is to evaluate the effect of guselkumab on coronary flow reserve (CFR), measured by transthoracic doppler-echocardiography, in participants with moderate-to-severe psoriasis and intermediate cardiovascular risk.
Key Dates
- Start date
- Nov 23, 2021
- Status verified
- Mar 2025
- Primary completion
- Jul 28, 2023
- Completion
- Jul 28, 2023
Study Design
- Enrollment
- 15 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: GuselkumabParticipants will receive guselkumab 100 milligrams (mg) by subcutaneous injection at Weeks 0, 4, 12, 20 and 28.
Primary Outcome Measure
Change From Baseline in Coronary Flow Reserve (CFR) at Week 32 [ Time Frame: Baseline (Week 0) and Week 32 ]
Related Studies
- Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy ProjectRecruiting · University of California, San Diego · La Jolla, California
- Regulation of Inflammatory Genes in PsoriasisRecruiting · University of Alabama at Birmingham · Birmingham, Alabama
- LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe PsoriasisEnrolling By Invitation · Bausch Health Americas, Inc. · Bridgewater, New Jersey
- An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis PatientsRecruiting · Psoriasis Treatment Center of Central New Jersey · East Windsor, New Jersey